Oct 03, 2018 - The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.
Oct 02, 2018 - Regeneron is part of a pack of new checkpoint inhibitor developers in solid tumor oncology.Their entry to the PD-1 space recently was approved for a new indication in the field.What does it mean for t
Oct 01, 2018 - Sanofi (SNY)/Regeneron's (REGN) anti- PD-1 drug cemiplimab wins FDA approval for a type of skin cancer.
Sep 27, 2018 - Allergies are on the rise and researchers are trying new methods to help combat potentially life threatening reactions.
Sep 25, 2018 - The FDA has lifted clinical hold on Sarepta's (SRPT) clinical study evaluating the Duchenne muscular dystrophy micro-dystrophin gene therapy program. The clinical hold was placed in July by the FDA.
Sep 24, 2018 - The CHMP re-confirmed the negative opinion for Sarepta's (SRPT) Exondys, which is developed to treat individuals who have a specific type of Duchenne muscular dystrophy.
Sep 24, 2018 - Novartis (NVS) gets positive CHMP opinion for a label expansion of Gilenya, gene therapy, and a biosimilar of Neulasta.
Sep 20, 2018 - The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
Sep 19, 2018 - Eylea represents a significant portion of revenue and will face upcoming competition, which could slow Regeneron sales growth over the coming years.Eylea recently received approval for a 12 week dose,
Sep 19, 2018 - Regeneron and Amgen are better picks than Biogen.The refiners are doing well.Book profits on Liberty Oilfield Services.